Neuropathologic changes of multiple system atrophy and diffuse lewy body disease

Seminars in Neurology

Volumn 34, Issue 2, 2014, Pages 210-216

  Ramirez, Etty Paola Cortes ^a   Vonsattel, Jean Paul G ^a  

^a Department of Medicine   (United States)

Author keywords

diffuse Lewy body disease; glial cytoplasmic inclusions; Lewy body; multiple system atrophy; neuropathology; selective vulnerability

Indexed keywords

ALPHA SYNUCLEIN;

BRAIN; BRAIN ATROPHY; BRAIN CORTEX; BRAIN STEM; CEREBELLUM; CORPUS STRIATUM; DIFFUSE LEWY BODY DISEASE; GENETIC TRAIT; HUMAN; MESENCEPHALON; NERVE CELL; NEUROPATHOLOGY; OLIGODENDROGLIA; OLIVOPONTOCEREBELLAR ATROPHY; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SHY DRAGER SYNDROME; PATHOLOGY;

BRAIN; HUMANS; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY; NEURONS;

EID: 84903272888     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0034-1381732     Document Type: Review

References (37)

1. Vonsattel J. PG, Del Amaya M. P., Keller C. E. Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol: 2008; 115 5 509 532
2. Mirra S. S., Heyman A., McKeel D., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology: 1991; 41 4 479 486
3. Hyman B. T., Phelps C. H., Beach T. G., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement: 2012; 8 1 1 13
4. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol: 2006; 112 4 389 404
5. The National Institute on Aging; Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging: 1997; 18 (4, Suppl) S1 S2
6. Trojanowski J. Q., Revesz T.. Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol: 2007; 33 6 615 620
7. McKeith I. G., Dickson D. W., Lowe J., et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology: 2005; 65 12 1863 1872
8. Braak H., Del Tredici K., Rüb U., de Vos R. AI, Jansen Steur E. N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging: 2003; 24 2 197 211
9. Papp M. I., Lantos P. L. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci: 1992; 107 2 172 182
10. Lantos P. L., Papp M. I. Cellular pathology of multiple system atrophy: a review. J Neurol Neurosurg Psychiatry: 1994; 57 2 129 133
11. Dickson D. W., Liu W., Hardy J., et al. Widespread alterations of α-synuclein in multiple system atrophy. Am J Pathol: 1999; 155 4 1241 1251
12. Wenning G. K., Tison F., Ben Shlomo Y., Daniel S. E., Quinn N. P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord: 1997; 12 2 133 147
13. Poston K. L., Tang C. C., Eckert T., et al. Network correlates of disease severity in multiple system atrophy. Neurology: 2012; 78 16 1237 1244
14. Iodice V., Lipp A., Ahlskog J. E., et al. Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. J Neurol Neurosurg Psychiatry: 2012; 83 4 453 459
15. Gilman S., Wenning G. K., Low P. A., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology: 2008; 71 9 670 676
16. Jellinger K. A., Seppi K., Wenning G. K. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord: 2005; 20 12 S29 S36
17. Wenning G. K., Stefanova N., Jellinger K. A., Poewe W., Schlossmacher M. G. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol: 2008; 64 3 239 246
18. Duda J. E., Giasson B. I., Gur T. L., et al. Immunohistochemical and biochemical studies demonstrate a distinct profile of α-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol: 2000; 59 9 830 841
19. Armstrong R. A., Cairns N. J., Lantos P. L. Multiple system atrophy (MSA): topographic distribution of the α-synuclein-associated pathological changes. Parkinsonism Relat Disord: 2006; 12 6 356 362
20. Nirenberg M. J., Libien J., Vonsattel J-P, Fahn S. Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation. Mov Disord: 2007; 22 2 251 254
21. Yoshizawa H., Vonsattel J. P., Honig L. S. Early neuropsychological discriminants for Lewy body disease: an autopsy series. J Neurol Neurosurg Psychiatry: 2013; 84 12 1326 1330
22. Johnson D. K., Morris J. C., Galvin J. E. Verbal and visuospatial deficits in dementia with Lewy bodies. Neurology: 2005; 65 8 1232 1238
23. Litvan I., MacIntyre A., Goetz C. G., et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol: 1998; 55 7 969 978
24. Brown D. F., Dababo M. A., Bigio E. H., et al. Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J Neuropathol Exp Neurol: 1998; 57 1 39 46
25. Jellinger K. A. Lewy body-related α-synucleinopathy in the aged human brain. J Neural Transm: 2004; 111 10-11 1219 1235
26. Lippa C. F., Duda J. E., Grossman M., et al. DLB/PDD Working Group. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology: 2007; 68 11 812 819
27. McKeith I., Mintzer J., Aarsland C., et al. Dementia with Lewy bodies. Lancet Neurol: 2004; 3 19 28
28. Forno L. S. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol: 1996; 55 3 259 272
29. Gómez-Tortosa E., Irizarry M. C., Gómez-Isla T., Hyman B. T. Clinical and neuropathological correlates of dementia with Lewy bodies. Ann N Y Acad Sci: 2000; 920 9 15
30. Kosaka K., Iseki E. Clinicopathological studies on diffuse Lewy body disease. Neuropathology: 2000; 20 1 1 7
31. Gómez-Isla T., Growdon W. B., McNamara M., et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology: 1999; 53 9 2003 2009
32. Del Tredici K., Rüb U., De Vos R. AI, Bohl J. RE, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol: 2002; 61 5 413 426
33. Dickson D. W., Ruan D., Crystal H., et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology: 1991; 41 9 1402 1409
34. Hansen L., Salmon D., Galasko D., et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology: 1990; 40 1 1 8
35. Clark L. N., Kartsaklis L. A., Wolf Gilbert R., et al. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol: 2009; 66 5 578 583
36. Sharp M. E., Marder K. S., Cote L., et al. Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation. Mov Disord: 2014; 29 4 566 568
37. Poulopoulos M., Cortes E., Vonsattel J-PG., et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J Mol Neurosci: 2012; 47 1 139 143